Technical analyst PN Vijay has maintained 'buy' rating on Aurobindo Pharma Limited stock to attain a target of Rs 300.

According to analyst, the said target can be achieved within a period of 12 to 18 months.

The stock of the bank, on April 27, closed at Rs 195.20 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 19.31 and 10.19 respectively.

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Technical analyst Gaurang Shah of Geojit BNP Paribas has maintained 'buy' rating on Aurobindo Pharma Limited stock for 15-20% returns.

According to analyst, the interested investors can buy the stock on dips to around Rs 165.

Today, the stock of the company opened at Rs 171.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Current EPS & P/E ratio stood at 19.31 and 9.02 respectively.

Angel Broking recommends `Buy’ on Aurobindo Pharmaceuticals. The broking firm has predicted that the stock may reach a price target of Rs 210 soon. It has mentioned in the recent report of the broking firm dated Feb. 25, 2011. Aurobindo Pharma (APL) has announced that it has received an import alert for the detention of products from its Cephalosporin facility (Unit VI).

The USFDA has imposed this import alert on Aurobindo Pharma (APL). Its Cephalosporin facility is located in Andhra Pradesh, India.

Technical analyst Anil Singhvi has maintained 'buy' rating on Aurobindo Pharma Limited stock with an intraday target of Rs 1240.

According to analyst, the investors can purchase the stock with a stop loss of Rs 1154.

The stock of the bank, on February 04, closed at Rs 1175 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1375 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 96.56 and 12.25 respectively.

Aurobindo Pharma Limited has bagged tentative nod from the US Food & Drug Administration to make and sell Levofloxacin tablets in the American market.

The company bagged nod to manufacture and market the drug, the generic equivalent of Ortho McNeil Janssen Pharmaceutical Inc's Levaquin pills, in the potencies of 250mg, 500mg and 750mg.

Levofloxacin pills 250mg, 500mg, and 750mg are suggested to cure bacterial illnesses including chronic bronchitis, bacterial sinusitis, pneumonia, skin and skin structure diseases in grownups.

Aurobindo Pharma Ltd (APL) started as a pure API supplier has now scaled its business to focus more on formulations. The company has a strong presence in the antibiotic space especially in the segments of penicillin and cephalosporins and the anti-retroviral segment. After establishing a presence in the semi regulated markets, the company began to venture into the regulated markets of US and Europe and these are expected to become key growth drivers going forward. Till date, it has commercialized over 200 API's and 300 formulation products with 15 manufacturing facilities across the globe approved by USFDA and other regulators.

Technical analyst Hemen Kapadia has maintained 'buy' rating on Bharti Airtel Limited stock with an intra-day target of Rs 1350.

According to analyst, the stock can be purchased at Rs 1334 with a stop loss of Rs 1326.

The stock of the company, on December 21, closed at Rs 1334.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.85 on BSE.

Current EPS & P/E ratio stood 81.76 and 16.18 respectively.

Technical analyst Ashish Chaturmotha of Anand Rathi Securities has maintained 'buy' rating on Aurobindo Pharma Limited with a short term target of Rs 1350.

The analyst said that the stock can be purchased with a stop loss of Rs 1250.

Today, the stock of the company opened at Rs 1280 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.44 respectively.

Technical analyst Kunal Sarogi has maintained 'buy' rating on Aurobindo Pharma Ltd stock with a stop loss of Rs 1200.

According to analyst, the investors can buy the stock with a target of Rs 1370.

Today, the stock of the company opened at Rs 1249.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.22 respectively.

Stock market analyst Rajesh Gupta of Fairwealth Securities has maintained 'buy' rating on Aurobindo Pharma Limited stock with a target of 1,130.

According to analyst, the interested investors can buy the stock above Rs 1085 with a strict stop loss of Rs 1069.90.

The stock of the company, on Sep 20, closed at Rs 1094.45 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1109.85 and a low of Rs 680 on BSE.

Current EPS & P/E ratio stood at 79.40 and 13.78 respectively.

Leading drug maker of the country, Aurobindo Pharma has informed that there has been a huge decline in its net profit figure. It has declared its first quarter financial results for the financial year 2010-11.

The company has posted a net profit of Rs 51.50 crore for the June quarter of the year which is almost 69.08% decline from the net profit registered by the same company a year ago in the similar fiscal year. However, there has been a hike in the net sales of the company in this Q1.

Aurobindo Pharma has declared that the US FDA has given tentative nod for Rosuvastatin Calclum pills in strengths of 5mg, 10mg, 20mg and 40mg.

According to the company, Resuvastatin Calclum tabs, which comes under cardio vascular (CVS) therapeutic family, treats high LDL cholesterol and total cholesterol level.

For the year ended Dec 31, 2009, Resuvastatin Calclum tabs hold a market size of $ 2.9 billion in the United States.

Company was founded in 1986 by Mr. P. V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly commited professionals; Aurobindo Pharma became a public company in 1992. Aurobindo Pharma Limited based at Hyderabad, India manufactures generic pharmaceuticals and Active Pharmaceutical Ingredients. Company is one of the world's top 5 manufacturers of semi synthetic penicillin’s. Company has Asia's largest sterile API facility. It is one of India’s top 5 pharma companies ranked in terms of turnover.

Aurobindo Pharma Ltd., which is primarily based in India, has reportedly received the final nod for its anti - allergic drug, Cetirizine Hydrochloride Solution from the USFDA. The approval for the drug is under the OTC category which is also called the over - the - counter category for products.

Aurobindo Pharma has got the final nod from the US drug regulator for its anti-allergic syrup in the potency of 1mg/ml.

In a declaration, the company news, "The company has received final approval for Cetirizine Hydrochloride syrup from the US Food and Drug Administration (FDA)."

Cetirizine Hydrochloride syrup, which comes under the anti- allergic sector, is prescribed for the treatment of symptoms linked with seasonal rhinitis in grownups as well as kids aged over two years.

Indian pharmaceutical company Aurobindo Pharma has got tentative nod approval from USFDA to market Perindopril Erbumine tabs in the strengths of 2 mg, 4 mg and 8 mg respectively.

Perindopril Erbumine tabs, which come under CVS section, are the generic versions of Solvay Pharmaceuticals' 'Aceon' tabs.

Perindopril Erbumine is prescribed for treating patients suffering from high blood pressure.

The company said that the product will be launched shortly.

Aurobindo Pharma has informed that it has secured nod from the US Food & Drug Administration (USFDA) for its chewable and dispersible Lamotrigine tablets in the strength of 5mg and 25mg respectively.

The drug is the generic equivalent of Lamictal CD tablets, and used in the treatment of partial and generalized seizures.

The company stated in a communiqué that it will launch Lamotrigine tablet, which comes under the central nervous system (CNS) segment, soon in the market.

Aurobindo Pharma, leading Hyderabad based drug firm, has announced that it has got approval from South African (SA) Medicines Control Council to manufacture and sell two drugs in South Africa.

The approval has been granted for Auro Ampicillin injection in potency of 500 mg and 1,000 mg Auropidone tablets in 0.5 mg strength.

Auro Ampicillin injection is an antibiotic which is indicated in the treatment of bacterial infections and Auropidone tablets, fall under central nervous system (CNS) category.

With this approval, the pharma major (Aurobindo Pharma) now has a total of 37 products sanctioned by the MCC.

The sources informed Medicines Control Council (MCC) is a statutory body that was set up to oversee the regulation of medicines in South Africa.

Aurobindo Pharma has received the tentative approval for Atomoxetine Hydrochloride 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg and final approvals for Ribavirin tablets 200mg and Ribavirin Capsules 200mg from USFDA.

Atomoxetine Hydrochloride Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80 mg and 100mg are generic equivalent to Strattera of Eli Lily. However, Aurobindo Shares 180 days exclusivity with other generic companies subject to the final approval and launch based on the pending litigation with Eli Lilly.

Swissmedic, Switzerland government agency for therapeutic products, has allowed India based Aurobindo Pharma Limited for marketing and branding amlodipine and metformin tablets. The drug manufacturer has already two drugs approved by Swiss drug regulator, Swissmedic.

The company, on Monday, also got approval from US drug regulator, the U. S. Food and Drug Administration for its product Risperidone oral solution, a drug used in the treatment of schizophrenia. Risperdal is a brand of Johnson & Johnson's Ortho-McNeil-Janssen which is a generic version of Risperdal oral solution 1mg/ml of Ortho- McNeil Janssen.